High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization
Why the study?
Does platelet function monitoring with antiplatelet drug adjustment reduce ischemic recurrences in patients undergoing coronary stenting?
Population
2,440 patients undergoing coronary stenting
Comparison
Platelet function monitoring with antiplatelet… vs Conventional antiplatelet strategy without…
Design
RCT, Randomized before coronary stenting
Follow-up
through 1 year
Authors
Discussion
Loading...
Member takes
Implication
Routine platelet function monitoring does not improve post-stenting ischemic outcomes; confirms no benefit of guided antiplatelet adjustment in this RCT.
Structured PICO
Does platelet function monitoring with antiplatelet drug adjustment reduce ischemic recurrences in patients undergoing coronary stenting?
P
Population
2,440 patients undergoing coronary stenting
I
Intervention
Platelet function monitoring (VerifyNow P2Y12/aspirin point-of-care assay) with antiplatelet drug adjustment in suboptimal responders
C
Comparator
Conventional antiplatelet strategy without platelet function monitoring and without drug or dose changes
O
Outcome
Composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization through 1 year (evaluated via landmark analysis starting at hospital discharge)composite
Routine platelet function monitoring with subsequent antiplatelet therapy adjustment does not improve 1-year ischemic outcomes after hospital discharge in patients undergoing coronary stenting.
Cite This Study
Montalescot et al. (2014) studied this question.